AdvaMed questions public data for product coverage
This article was originally published in Clinica
Executive Summary
AdvaMed has drafted criteria for Medicare to use in deciding whether to accept external data by the public to verify or amend reimbursement rates. The Centers for Medicare & Medicaid Services (CMS) currently uses external data only on rare occasions, and the trade group wants the agency to better explain what data it finds most useful.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.